Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Autolus Therapeutics's total debt was $380.00K at Sep 30, 2018. For fiscal 2018 it was $380.00K, down 50.2% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $380.00K | -50.2% |
| FY2017 | Sep 30, 2017 | $763.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $380.00K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $763.00K | – |
See a number that looks wrong?